IDH2 and acute myeloid leukemia: A phase 1 clinical study revealed that ivosidenib or enasidenib in combination with standard induction chemotherapy and consolidation therapy showed 73–93% CR/CRh rates with 58–89% minimal residual disease (MRD)-negative rates in patients with IDH1- or IDH2-mutated newly diagnosed AML [37].